

DD-1056
TXR-4075

10-5-84



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

004075

OFFICE OF
PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM

October 5, 1984

Subject: Diflubenzuron 6F1832: Review of the Lifetime Oncogenic Study of Diflubenzuron in Mice and Request for Deleting Some Precautionary Label Statements
Accession No. 253570, 253571, 253572, 253573, 253574, 253575, and 253576. Caswell No. 346A.

To: Timothy Gardener, PM #17
Registration Division (TS-767)

Thru: David Ritter, Acting Section Head
Review Section #1
Toxicology Branch/HED (TS-769) *DR 10-31-84*

From: John H.S. Chen, D.V.M.
Review Section #1
Toxicology Branch/HED (TS-769) *John H. Chen*

Toxicology Branch Recommendation:

1. The registrant should be apprised of the deficiencies in the lifetime oncogenicity study of Diflubenzuron in mice, Huntingdon Research Center Report No. PDR 360/831096/B, May 15, 1984.
2. The subject labeling should not be deleted until all the toxicity data requested in 1979 have been received and reviewed.

10821

004075

Review and Assessment of the Life Time Oncogenic Study of Diflubenzuron in Mice
 (Huntingdon Research Center Report No. PDR 360/831096/B, May 15, 1984 - Total
 Duration of Dietary Intake: 91 Weeks)

Procedure:

The procedures used in the lifetime oncogenicity study of Diflubenzuron in the HC/CFLP mice are identical to those described previously in the 52-week Interim Report (HRC Report No. 360/821141, 56645/18/83, Accession No. 250270, 250271, and 250272).

Results:

1. Clinical Signs

The blue/gray discoloration of the extremities and dark eyes found in the treated animals during the first year of study have been previously recorded in the interim 52-week report. No other changes in the incidental clinical-signs were observed in animals of all groups during the second year of this study (52-91 weeks).

2. Mortality

<u>Dose Group (ppm)</u>	<u>No. of Animals (dead/tested)*</u>	
	<u>Males</u>	<u>Females</u>
0	40/104	44/104
16	12/52	24/52
80	17/52	27/52
400	25/52	19/52
2000	14/52	30/52
10000	17/52	23/52

* Main group

Findings: No obvious treatment-related-effect on mortality was observed during the 1-78 weeks of study.

3. Body Weights

<u>Dose Group (ppm)</u>	<u>Mean Weekly Body Weights (g) (Weeks)</u>				
	<u>1</u>	<u>26</u>	<u>52</u>	<u>78</u>	<u>92</u>
(Males)					
0	37	57	67	67	66
16	38	59	67	67	62
80	38	58	65	67	69
400	39	58	65	66	64
2000	39	58	65	66	66
10000	38	57	64	64	63
(Females)					
0	33	47	54	56	61
16	33	49	57	59	62
80	33	49	58	60	56
400	33	48	56	59	53
2000	33	48	56	58	61
10000	33	48	55	56	56

2

004075

3. Body Weights - Continued

Findings: There were no significant differences in the mean body weight values between the treated and control groups (both sexes) during the study.

4. Food Consumption

Dose Group (ppm)	Mean Weekly Food Consumption Values (g) (Weeks)				
	1	25	52	78	92
(Males)					
0	30	32	34	36	36
16	31	32	32	36	36
80	31	32	33	37	40
400	30	30	32	38	42
2000	31	31	35	39	42
10000	30	32	34	38	40
(Females)					
0	27	29	33	38	38
16	28	30	31	38	44
80	30	29	33	39	40
400	29	30	30	38	34
2000	30	30	33	44	39
10000	30	31	32	41	43

Findings: No significant differences in the mean weekly food consumption values were observed between the treated and control groups (both sexes) during the study.

5. Hematology(a) Mean Clinical Hematology Values of Male Mice at Week 91

Dose (ppm)	0	16	80	400	2000	10000
PCV (%)	41.0	39.0	42.0	42.0	37	36*
Hb (g%)	13.9	13.0	13.2	14.0	12.4	13.0
RBC (10^6 /CMM)	7.3	6.8	7.2	7.6	6.0*	6.3*
MCHC (%)	33.5	33.5	31.5	33.1	33.0	36.6*
MCH (Pg)	19.1	19.2	18.4	18.8	20.8*	20.7*
MCV (fl)	58.0	58.0	59.0	57.0	64.0	56.0
WBC (10^3 /CMM)	7.1	4.0	7.5	12.4	8.9	6.3
Plats (10^3 /CMM)	1155	1296	1305	1413*	1484*	1368*
S-Hb (% H _b)	0.10	0.13	0.34*	1.27*	3.45*	4.06*
Met-Hb(% Hb)	1.36	1.38	1.78*	2.96*	4.27*	5.92*

*Significant changes: PCV - Packed Cell Volume; Hb - Hemoglobin; RBC - Red Blood Cell; MCHC - Mean Corpuscular Hemoglobin Concentration; MCH - Mean Corpuscular Hemoglobin; MCV - Mean Corpuscular Volume; WBC - White Blood Cell; Plats - Platelet; S-Hb - Sulfhemoglobin; Met-Hb - Methemoglobin.

3

004075

5. Hematology - Continued

Findings for Male Mice: The mean PCV values and RBC counts were decreased in the 2000 and 10000 ppm level groups at week 52 and a similar trend of decrease in these values was also observed in the same level groups at week 91. The mean corpuscular hemoglobin concentration and the mean corpuscular hemoglobin were found to be consistently higher in the 2000 and 10000 ppm level groups from the week 52 to week 91 when compared with that of the control group. There was a treatment-related increase in the platelet count among mice treated with 400, 2000, and 10000 level groups in weeks 26, 52, 78, and 91. The Heinz Bodies were also detected in samples from mice treated with 2000 and 10000 ppm level groups in weeks 52, 78, and 91. A dose-related elevation of methemoglobin and sulfhemoglobin was consistently observed in weeks 26, 52, 78 and 91.

(b) Mean Clinical Hematology Values of Female Mice at Week 91

<u>Dose (ppm)</u>	<u>0</u>	<u>16</u>	<u>80</u>	<u>400</u>	<u>2000</u>	<u>10000</u>
PCV (%)	42.0	44.0	43.0	44.0	41.0	40.0
Hb (g%)	13.7	14.0	14.1	14.7	13.8	14.2
RBC (10^6 /CMM)	7.5	7.6	7.8	7.5	7.0	6.7*
MCHC (%)	32.4	31.8	32.5	33.5	34.0	35.9*
MCH (Pg)	18.4	18.6	18.1	19.6*	19.8*	21.1*
MCV (fl)	57.0	58.0	56.0	59.0	58.0	59.0
WBC (10^3 /CMM)	5.4	5.7	8.2	8.7	8.9	8.8
Plats (10^3 /CMM)	791	916	690	1315*	1446*	1457*
Met - Hb (%Hb)	0.77	0.89	1.43*	2.76*	4.36*	5.4*
S - Hb (%Hb)	0.12	0.12	0.22	1.75*	3.94*	3.6*

* Significant changes

Findings for Female Mice: The mean PCV values for the 2000 and 10000 ppm level groups were significantly lower than that of the control group at week 52. But, no significant difference in these values was observed in the same treated groups at week 91 when compared with that of the control group. The mean RBC counts were significantly decreased in the 2000 and 10000 ppm level groups at week 52. But, significant decrease in these values was only observed in the 10000 ppm level group at week 91. The MCHC and the MCH values were found to be consistently higher in the 10000 ppm level group when compared with that of the control group from the week 52 to week 91. There was a treatment-related increase in the platelet count among mice treated with 400, 2000, and 10000 ppm Dimilin in weeks 26, 52, 78, and 91. The Heinz Bodies were found consistently in samples from mice treated with 2000 and 10000 ppm Dimilin in weeks 52, 78 and 91. A dose-related elevation of methemoglobin and sulfhemoglobin was consistently observed in weeks 26, 52, 78 and 91.

5. Hematology - Continued(c) Methemoglobin and Sulfhemoglobin Values at the Week 52, 78 and 91

<u>Dose (ppm)</u>	<u>0</u>	<u>16</u>	<u>80</u>	<u>400</u>	<u>2000</u>	<u>10000</u>
<u>Males</u>						
Metheme (52 Week)	0.57	0.84*	1.54*	3.25*	4.11*	6.38*
" (78 ")	0.66	0.87	1.37*	2.34*	3.17*	4.63*
" (91 ")	1.36	1.38	1.78*	2.96*	4.27*	5.92*
Sulfheme (52 Week)	0.27	0.61*	1.55*	3.30*	4.03*	6.32*
" (78 ")	0.12	0.17	0.41*	4.01*	3.75*	6.35*
" (91 ")	0.10	0.13	0.34*	1.27*	3.45*	4.06*
<u>Females</u>						
Metheme (52 Week)	0.45	0.63	1.13*	2.45*	5.06*	6.25*
" (78 ")	1.34	1.35	1.88*	3.62*	5.18*	6.04*
" (91 ")	0.77	0.89	1.43*	2.76*	4.36*	5.40*
Sulfheme (52 Week)	0.21	0.46*	1.40*	3.17*	6.33*	8.36*
" (78 ")	0.13	0.61	0.59*	3.01*	3.52*	5.72*
" (91 ")	0.12	0.12	0.22	1.75*	3.94*	3.60*

* Significantly dose-related increase

6. Blood Chemistry

Significantly higher Alkaline Phosphatase (AP) activities, Glutamic-Provic Transaminase (GPT) activities and Cholesterol values were observed in weeks 24 and 50 for mice treated with 10000 ppm of Diflubenzuron. But, in week 89, no significant increases in these enzymatic activities was found in the same treated group except the marginal increase of cholesterol values in male mice. The AP activities, the GPT activities, and Cholesterol value among female mice continued to show no sign of treatment-related effects at week 89. No treatment-related effects on other parameters (i.e., glucose, protein, albumin, urea nitrogen, and glutamic-oxaloacetic transaminase activity) were observed during the study.

7. Urinalysis

There were no significant differences in mean (group) urinalysis values (i.e., pH, specific gravity, and protein) between the treated and control groups of both sexes in weeks 51 and 90.

5

004075

8. Gross Pathology(a) Incidence Summary of Gross Pathology for Animals Dying Prior to Study Termination

Macropathology	Males (ppm)						Females (ppm)					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
No. Examined	67	29	33	36	31	36	79	36	41	36	45	42
No. Not Remarkable:												
<u>Stomach</u>												
Mass	-	1	-	-	-	-	-	-	1	1	1	-
Limiting Ridge Prominent/Thickened	21	8	6	6	10	13	32	9	14	8	8	11
<u>*Liver</u>												
Mass/Nodule	16	9	8	15	10	16*	5	5	6	2	4*	6*
Enlarged	19	7	9	5	9	15*	14	7	12	9	14*	9*
Pale	14	4	5	7	8	7	17	10	6	13	6	9
Surface Irregular/Pitted	5	3	2	1	2	6	13	7	5	4	9	11
<u>*Lungs</u>												
Mass/Nodule	11	2	7	8	3	6	12	6	6	8	6	6
Congested	5	2	5	4	2	7*	5	3	3	6	9*	7*
<u>Kidneys</u>												
Enlarged	11	5	8	6	6	4	6	-	4	2	3	3
Uniform Cortical Scarring	3	4	6	4	4	5	10	1	4	3	2	5
<u>Lymph Nodes</u>												
Regionally Enlarged/15	10	11	10	11	7	7	27	9	9	7	12	8
Congested/Cystic												
Generally Enlarged/Congested/Cystic	16	3	3	2	6	7	13	10	14	4	13	8
<u>*Spleen</u>												
Enlarged	34	17	18	18	26	30*	53	23	30	24	40*	37*
Dark	-	-	-	-	1	3*	-	-	-	-	2*	1*
<u>Heart</u>												
Enlarged	2	1	-	1	2	2	4	-	2	-	-	3
<u>Adrenals</u>												
Enlarged	1	-	-	-	-	-	5	1	6	3	2	3
<u>Pituitary</u>												
Enlarged	-	1	-	-	-	1	6	4	2	5	2	2
<u>Urinary Bladder</u>												
Mass	-	-	-	1	-	-	4	1	1	-	-	1
<u>Testis</u>												
Mass	1	1	-	1	-	1	0	0	0	0	0	0
<u>Seminal Vesicle</u>												
Distended/Enlarged	5	4	5	3	3	1	0	0	0	0	0	0
<u>*Ovaries</u>												
Mass	0	0	0	0	0	0	9	3	2	3	3	1
Enlarged	0	0	0	0	0	0	3	1	2	1	5	4*

6

004075

8. Gross Pathology - Continued

<u>Macropathology</u>	<u>Males (ppm)</u>						<u>Females (ppm)</u>					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
<u>Uterus</u>												
<u>Mass</u>	0	0	0	0	0	0	6	6	3	3	5	4
<u>Thymus</u>												
<u>Enlarged</u>	1	1	3	-	1	1	1	1	3	1	3	2
<u>*Skin</u>												
<u>*Cyanosis</u>	-	-	-	1	6*	4*	-	-	-	1	2*	3*
<u>Subcutis</u>												
<u>Mass</u>	2	2	1	1	2	-	4	1	3	-	2	2
<u>Thoracic cavity</u>												
<u>Mass</u>	9	1	1	4	-	4	10	6	7	7	1	3

7

004075

8. Gross Pathology - Continued(b) Incidence Summary of Gross Pathology for Animals Sacrificed at Study Termination

Macropathology	Males (ppm)						Females (ppm)					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
No. Examined	37	27	19	16	21	16	25	16	11	16	7	10
No. Not Remarkable:												
<u>Stomach</u>												
Mass	1	-	1	-	1	-	-	-	-	-	-	1
Limiting Ridge Pro-												
minent/Thickened	2	2	2	1	-	-	1	1	-	1	-	2
<u>*Liver</u>												
Mass/Node	13	8	9	8	7	5	2	1	3	2	2	1
Enlarged	2	-	3	1	4	6*	1	1	-	1	-	4*
Pale	-	-	2	1	2	4	2	-	-	1	-	1
Surface Irregular/												
Pitted	1	1	1	-	3	3	4	2	1	1	1	4
<u>*Lungs</u>												
Mass/Node	9	10	4	6	8	4	5	4	-	6	3	3
Congested	-	-	2	-	1*	1*	-	-	-	-	-	-
<u>Kidneys</u>												
Enlarged	1	-	1	1	1	-	3	-	1	-	-	-
Uniform Cortical												
Scarring	2	-	1	4	1	3	1	-	1	-	-	1
<u>Lymph Nodes</u>												
Regionally Enlarged/	6	3	5	1	1	3	3	3	2	3	1	-
Congested/Cystic												
Generally Enlarged/												
Congested/Cystic	1	1	1	-	1	-	1	-	-	-	-	-
<u>*Spleen</u>												
Enlarged	11	8	10	10	14	10*	9	6	6	9	5*	9*
Dark	-	-	-	3	13	13*	-	-	-	2*	-	10*
<u>Heart</u>												
Enlarged	-	1	-	-	1	-	2	-	-	2	-	-
<u>Adrenals</u>												
Enlarged	-	-	-	-	-	-	-	1	-	1	-	-
<u>Pituitary</u>												
Enlarged	-	-	-	1	-	1	2	5	1	1	-	-
<u>Testis</u>												
Mass	-	1	-	-	2	-	0	0	0	0	0	0
<u>Seminal Vesicle</u>												
Distended/Enlarged	11	4	11	6	8	3	0	0	0	0	0	0
<u>Ovaries</u>												
Mass	0	0	0	0	0	0	1	-	-	-	-	-
Enlarged	0	0	0	0	0	0	3	-	1	2	-	1
<u>Uterus</u>												
Mass	0	0	0	0	0	0	2	-	-	-	1	-
<u>Thymus</u>												
Enlarged	-	-	-	-	-	-	-	-	-	-	-	-
<u>*Skin</u>												
Cyanosis	-	-	1	14	21*	16*	-	-	-	5*	7*	10*
<u>Subcutis</u>												
Mass	1	-	2	2	-	-	-	-	-	-	-	-
<u>Thoracic cavity</u>												
Mass	-	-	-	-	-	-	1	-	-	-	-	1

4

8. Gross Pathology - Continued

004075

(c) Summary of Gross Pathology Findings:

a) For Animals Dying Prior to Study Termination

There were increased incidences of enlarged livers, livers with nodule or mass, congested lungs, splenic enlargement, dark discoloration of the spleen, and cyanosis of the cutis in animals of both sexes treated with 2000 and 10000 ppm Diflubenzuron. The enlarged ovaries were also noted among females treated at 2000 and 10000 ppm. No other pathological findings were found to be significant in this study.

b) For Animals Sacrificed at Study Termination

Increased incidences of splenic enlargement, dark discoloration of the spleen, and cyanosis of the cutis were persistently observed in animals of both sexes treated with 2000 and 10000 ppm Diflubenzuron. Enlarged livers were also found in animals treated at 10000 ppm. Congested lungs were noted only among males treated with Diflubenzuron. No other pathological findings were found to be significant at terminal sacrifice.

004075

Organ Weights

Mean Values (g) for Animals Killed at Termination

Organ	Males (ppm)						Females (ppm)					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
Body Weight	64	61	65	62	64	61	54	59	53	53	54	52
Spleen	0.43	0.42	0.43	0.43	0.43	0.42	0.45	0.43	0.44	0.44	0.45	0.46
Adipose (mg)	3.9	3.8	3.6	3.7	3.8	3.84	5.5	6.3	4.1	4.5	4.2	4.5
Heart	0.32	0.31	0.33	0.33	0.34	0.36	0.25	0.25	0.23	0.24	0.26	0.27
Liver	0.35	0.38	0.38	0.36	0.33	0.33	0.31	0.30	0.29	0.34	0.34	0.38
Kidney	3.49	3.08	4.09	3.78	4.26*	5.01*	3.09	3.10	2.86	2.89	3.41*	3.52*
Spleen	0.29	0.31	0.54	0.36	0.38*	0.44*	0.30	0.30	0.40	0.40	0.47*	0.44*
Testis (mg)	37.2	37.6	38.2	40.2	30.6	30.0	38.1	35.1	32.5	36.0	31.5	38.2
Ovary	1.09	1.07	1.18	1.17	1.16	1.14	1.15	0.8	0.77	0.72	0.67	0.78
Uterus (mg)	9.7	9.3	9.6	10.3	10.5	9.7	12.0	12.5	13.1	9.5	12.2	14.1
Adipose (mg)	8.9	8.7	9.8	8.5	9.5	10.2	16.6	17.9	17.4	16.8	16.7	17.5
Adipose	0.38	0.36	0.41	0.35	0.43	0.45	26.1	17.5	21.5	21.8	24.3	23.4
Adipose	0.30	0.30	0.33	0.29	0.31	0.28	0.31	0.29	0.27	0.29	0.28	0.29

Significant increase

Findings: Although no treatment-related effect on liver weights and spleen weights among treated mice was demonstrated, the increased spleen weights and liver weights from the treated mice of both sexes receiving 2000 and 10000 ppm flubenzuron were significantly higher than those of the control groups at terminal kill.

p

004075

Individual Histopathological Findings Related to the Neoplastic Lesions for Animals
Found Dead or Sacrificed in Extremis During the Weeks 1-94

Dose Levels (ppm)	Males						Females					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
<u>*Lymphoreticular Tumour</u>												
Lymphosarcoma (D)	29	6	12	10	12	12	33	12	18	9	16	14
	67	29	33	36	31	36	79	36	41	36	45	42
" (T)	3	3	3	2	3	1	3	1	3	2	0	1
	37	23	19	16	21	16	25	16	11	16	7	10
*Reticulum Cell Sarcoma(D)	6	4	2	1	3	6	6	3	5	6	7	1
	67	29	33	36	31	36	79	36	41	36	45	42
" (T)	5	1	5	0	1	1	2	1	0	2	0	0
	37	23	19	16	21	16	25	16	11	16	7	10
Lymphoid Leukaemia (D)	0	2	1	0	0	0	3	3	0	2	2	1
	37	29	33	36	31	36	79	36	41	36	45	42
<u>*Lungs</u>												
*Pulmonary Adenocarcinoma(D)	7	3	7	6	1	0	5	5	5	4	4	4
	67	29	33	36	31	36	79	36	41	36	45	42
" (T)	7	9	4	2	6	2	3	2	0	5	3	3
	37	23	19	16	21	16	25	16	11	16	7	10
*Pulmonary Adenoma (D)	0	0	0	0	1	2	2	1	0	2	1	2
	67	29	33	36	31	36	79	36	41	36	45	42
" (T)	0	1	0	1	0	0	0	0	1	1	0	0
	37	23	19	16	31	16	25	16	11	16	7	10
<u>Liver</u>												
Malignant Liver Cell Tumour (D)	5	3	3	4	6	4	0	0	0	1	0	2
	67	29	33	36	31	36	79	36	41	36	45	42
Malignant Liver Cell Tumour (T)	3	2	2	5	3	1	0	0	0	0	0	0
	37	23	19	16	21	16	25	16	11	16	7	10
Benign Liver Cell Tumour (D)	3	1	2	4	3	2	0	1	1	1	0	0
	67	29	33	36	31	36	79	36	41	36	45	42
" (T)	4	4	3	2	0	2	1	0	1	0	1	0
	37	23	19	16	21	16	25	16	11	16	7	10
Haemangioma (D)	6	2	4	5	4	2	2	2	2	1	2	4
	67	29	33	36	31	36	79	36	41	36	45	42
" (T)	6	4	3	2	4	2	1	1	0	0	0	0
	37	23	19	16	21	16	25	16	11	16	7	10
<u>Lymph Nodes</u>												
Haemangiosarcoma (D)	0	0	1	0	0	0	0	0	0	0	0	0
	67	29	33	36	31	36	79	36	41	36	45	42
Haemangioma (T)	1	0	1	0	0	0	0	0	0	0	1	0
	37	23	19	16	21	16	25	16	11	16	7	10
<u>Kidneys</u>												
Renal Adenocarcinoma (D)	0	1	0	0	0	0	0	0	0	0	0	0
	67	29	33	36	31	36	79	36	41	36	45	42
Renal Adenoma (D)	0	0	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	0	0	79	36	41	36	45	42
<u>Testes</u>												
Interstitial Cell Adenoma(D)	1	0	1	2	0	0	0	0	0	0	0	0
	67	29	33	36	31	36	0	0	0	0	0	0
" (T)	3	2	1	1	2	1	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Seminoma (T)	0	0	0	0	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0

004075

Histopathological Findings to the Neoplastic Lesions - Continued

Dose Levels (ppm)	Males						Females					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
Adrenals												
Phaeochromocytoma (D)	1	0	0	0	1	2	1	0	0	0	0	0
	67	29	33	36	31	36	79	36	41	36	45	42
" (T)	0	0	0	0	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Cortical Adenoma (D)	1	0	0	1	1	0	0	0	0	0	0	0
	67	29	33	36	31	36	0	0	0	0	0	0
" (T)	1	1	1	0	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Stomach												
Squamous Cell Papilloma (D)	0	0	0	0	0	0	0	0	1	2	3	0
	0	0	0	0	0	0	79	36	41	36	45	42
Squamous Cell Papilloma (T)	1	0	1	0	2	0	1	1	0	0	0	1
	37	23	19	16	21	16	25	16	11	16	7	10
Skeletal Muscle												
Haemangioma (D)	0	1	1	0	0	0	0	0	0	0	0	0
	67	29	33	36	31	36	0	0	0	0	0	0
Skin/Subcutis												
Subcutaneous Haemangiosarcoma (D)	0	0	0	0	1	0	0	0	0	0	0	0
	67	29	33	36	31	36	0	0	0	0	0	0
Subcutaneous Haemangioma (D)	1	1	0	1	0	0	0	0	0	0	0	0
	67	29	33	36	31	36	0	0	0	0	0	0
Subcutaneous Haemangioma (T)	1	0	0	2	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Subcutaneous Fibrosarcoma (D)	1	0	0	1	0	0	0	1	0	0	0	0
	67	29	33	36	31	36	25	16	11	16	7	10
Subcutaneous Fibrosarcoma (T)	1	0	0	1	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Squamous Cell Papilloma (D)	0	0	0	0	0	0	0	0	1	0	0	1
	0	0	0	0	0	0	79	36	41	36	45	42
Squamous Cell Carcinoma (D)	0	0	0	0	0	0	0	0	1	1	0	1
	0	0	0	0	0	0	79	36	41	36	45	42
Pituitary												
Adenoma (D)	0	2	0	0	0	0	3	2	0	3	1	1
	67	19	33	36	31	36	79	36	41	36	45	42
" (T)	0	0	0	0	0	0	2	3	0	0	0	0
	0	0	0	0	0	0	25	16	11	16	7	10
Harderlin Gland												
Adenoma (D)	1	1	0	1	0	0	1	0	1	0	0	0
	67	29	33	36	31	36	79	36	41	36	45	42
Adenocarcinoma (D)	0	0	0	0	0	0	0	0	0	0	1	0
	0	0	0	0	0	0	79	36	41	36	45	42
Adipose Tissue												
Haemangioma (D)	1	0	0	0	1	0	1	0	0	0	0	0
	67	29	33	36	31	36	79	36	41	36	45	42
Spleen												
Haemangiosarcoma (D)	0	0	0	0	0	0	0	0	1	0	0	0
	0	0	0	0	0	0	79	36	41	36	45	42
" (T)	0	0	0	0	0	0	0	0	1	0	0	0
	0	0	0	0	0	0	25	16	11	16	7	10

12

10. Histopathological Findings to the Neoplastic Lesions - Continued

Dose Levels (ppm)	Males						Females					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
<u>Uterus</u>												
Haemangiosarcoma (D)	0/0	0/0	0/0	0/0	0/0	0/0	2/79	0/36	1/41	0/36	0/45	0/42
Haemangioma (D)	0/0	0/0	0/0	0/0	0/0	0/0	1/79	1/36	0/41	0/36	0/45	1/42
" (T)	0/0	0/0	0/0	0/0	0/0	0/0	1/25	0/16	1/11	0/16	0/7	0/10
Uterine Adenocarcinoma (D)	0/0	0/0	0/0	0/0	0/0	0/0	0/79	0/36	0/41	0/36	0/45	1/42
" (T)	0/0	0/0	0/0	0/0	0/0	0/0	0/25	0/16	0/11	1/16	0/7	0/10
Leiomyoma (D)	0/0	0/0	0/0	0/0	0/0	0/0	0/79	0/36	0/41	0/35	0/45	1/42
" (T)	0/0	0/0	0/0	0/0	0/0	0/0	0/25	0/16	0/16	0/16	1/7	0/10
<u>Ovaries</u>												
Malignant Granulosa Cell Tumour (D)	0/0	0/0	0/0	0/0	0/0	0/0	0/79	0/36	0/41	1/36	0/45	0/42
Granulosa Cell Tumour (D)	0/0	0/0	0/0	0/0	0/0	0/0	1/79	1/36	1/41	2/36	2/45	3/42
Granulosa Cell Tumour (T)	0/0	0/0	0/0	0/0	0/0	0/0	3/25	0/16	0/11	0/16	0/7	0/10
<u>Cervix</u>												
Fibrosarcoma (D)	0/0	0/0	0/0	0/0	0/0	0/0	0/79	0/36	0/41	0/36	1/45	0/42
<u>Thyroid</u>												
Follicular Adenoma (D)	0/0	0/0	0/0	0/0	0/0	0/0	0/79	0/36	0/41	0/36	1/45	0/42
<u>Mammary Gland</u>												
Mammary Adenocarcinoma (D)	0/0	0/0	0/0	0/0	0/0	0/0	2/79	1/36	3/41	0/36	0/45	1/42
Mammary Fibrosarcoma (D)	0/0	0/0	0/0	0/0	0/0	0/0	0/79	0/36	1/41	0/36	0/45	0/42

* Noticeable increase of incidence rate (%); (D) - Interim kill after 52 weeks of treatment; (T) - Terminal Kill.

004075

10. Histopathological Findings to the Neoplastic Lesions - ContinuedSummary of Neoplastic Findings:

The analysis of tumour data was based on the time-to-tumour method recommended by the International Agency for Research on Cancer (IARC, 1980). The results of the statistical analyses were initially assessed by calculating the P-values of the corrected Chi-Square in response over all the treated and control groups. If the significant level indicated a significant positive trend ($P < 0.05$) or indicated a negative trend ($P > 0.95$), the data were further examined by the statistical method of individual pair-wise comparisons. The following tumour types found in 5 or more mice of the same sex were selected for the statistical analyses.

a) Reticulum Cell Sarcoma (RCS)

A significant negative trend ($P = 0.95$) for RCS was found in the treated female groups. However, there was no significant difference in the incidence of this tumour type observed between the treated and control mice ($P = 0.06$ to 0.86).

b) Pulmonary Adenoma or Adenocarcinoma

A significant negative trend ($P = 0.98$) for Pulmonary Adenoma or Adenocarcinoma was detected in the treated male groups. No significant difference in the incidence of this tumour type was found between the treated and control mice ($P = 0.11$ to 0.81).

c) Phaeochromocytoma

A significant positive trend ($P = 0.0014$) for Phaeochromocytoma was detected in the treated male groups. However, this result was not significant when compared directly with the control group ($P = 0.12$ to 0.50).

d) Squamous Cell Papilloma (SCP)

A marginally negative trend ($P = 0.52$) for SCP was observed in the treated female groups. However, there was no significant difference in the incidence of this tumour type found between the treated and control mice at terminal kill.

Reference:

WHO International Agency for Research on Cancer (1980). Long-term and short-term screening assays for carcinogens: A critical appraisal. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Annex: R. Peto *et al.* Guidelines for simple sensitive experiments. Supplement 2. pp. 311-426.

14

11. Individual Histopathological Findings Related to the Nonneoplastic Lesions
for Animals Found Dead or Sacrificed in Extremis During the Weeks 1-94

Dose Levels (ppm)	Males						Females					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
<u>Heart</u>												
Myocarditis (D)	0	0	0	0	0	0	0	0	0	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11
" (T)	0	0	0	0	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	25	16	11	16	7	10
<u>*Lungs</u>												
Peribronchiolar Lymphoid	0	1	1	0	1	1	0	0	1	1	0	0
Aggregates (D)	20	10	11	10	11	10	18	8	10	11	11	11
Peribronchiolar Lymphoid	1	0	1	0	1	0	0	0	0	0	0	0
Aggregates (T)	37	23	19	16	21	16	25	16	11	16	7	10
Chronic Pneumonitis (D)	3	1	0	0	1	0	1	1	0	1	1	0
	20	10	11	10	11	10	18	8	10	11	11	11
*Chronic Pneumonitis (T)	7	6	5	7	9	5	12	7	4	2	1	2
	37	23	19	16	21	16	25	16	11	16	7	10
Perivascular Lymphoid	0	1	0	0	0	0	2	0	1	0	1	0
aggregations (D)	20	10	11	10	11	10	18	8	10	11	11	11
Perivascular Lymphoid	1	0	0	0	0	2	2	0	0	1	0	0
aggregations (T)	37	23	19	16	21	16	25	16	11	16	7	10
Chronic Pneumonia (D)	0	0	0	1	0	0	0	0	0	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11
" (T)	2	0	1	0	0	2	0	0	0	1	0	1
	37	23	19	16	21	16	25	16	11	16	7	10
Brown Pigmented Alveolar	1	0	0	0	0	0	0	0	0	0	0	0
Macrophages (D)	20	10	11	10	11	10	18	8	10	11	11	11
Brown Pigmented Alveolar	2	1	1	0	1	0	0	0	0	1	1	0
Macrophages (T)	37	23	19	16	21	16	25	16	11	16	7	10
Adenomatosis (D)	1	0	0	0	0	0	0	0	0	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11
" (T)	1	3	0	2	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	25	16	10	16	7	10
<u>Thymus</u>												
Medullary Hyperplasia (D)	0	0	0	0	0	0	0	2	0	0	0	0
	20	9	10	10	11	10	18	7	9	11	11	11
" (T)	2	1	0	1	1	0	3	4	0	3	1	0
	37	20	18	14	19	11	23	14	10	14	6	10
<u>Lymph Nodes</u>												
Lymphoid Hyperplasia (D)	2	0	0	1	0	0	0	1	0	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11
" (T)	4	3	5	1	1	3	0	0	1	3	0	0
	37	23	19	16	21	16	24	16	11	16	7	10
Cystic Degeneration (T)	1	1	3	0	2	0	5	5	2	2	0	0
	37	23	19	16	21	16	24	16	11	16	7	10
" (D)	0	0	0	0	0	0	1	1	1	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11
<u>*Spleen</u>												
*Extramedullary Haemopoiesis	1	0	0	4	3	3	0	1	0	2	3	7
(D)	20	10	11	10	11	10	18	8	10	11	11	11
*Extramedullary Haemopoiesis	4	2	6	4	6	9	7	4	1	5	5	5
(T)	37	23	19	16	21	16	25	16	11	16	7	10
*No. of Siderocytes (D)	0	0	0	5	8	9	0	0	0	0	8	10
	20	10	11	10	11	10	18	8	10	11	11	11

004075

15

11. Histopathological Findings to the Nonneoplastic Lesions - Continued

004075

Dose Levels (ppm)	Males						Females					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
*Spleen												
*No. of Siderocytes (T)	3	0	2	7	18	14	10	6	5	15	7	10
	37	23	19	16	21	16	25	16	11	16	7	10
Lymphoid Hyperplasia (D)	5	3	3	1	3	2	4	2	3	3	1	1
	20	10	11	10	11	10	18	8	10	11	11	11
" " (T)	14	4	3	4	0	1	5	4	0	4	0	2
	37	23	19	16	21	16	25	16	11	16	7	10
*Liver												
*Hepatocyte Enlargement (D)	9	5	7	4	7	9	1	0	2	2	4	5
	20	10	11	10	11	10	18	8	10	11	11	11
" " (T)	15	3	3	7	16	13	6	1	2	4	2	7
	37	23	19	16	21	16	25	16	11	16	7	10
*Extramedullary Haemo- poiesis (D)	0	0	0	2	0	1	0	0	0	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11
*Extramedullary Haemo- poiesis (T)	4	1	0	2	11	12	6	4	1	3	2	1
	37	23	19	16	21	16	25	16	11	16	7	10
Hepatic Leucocytosis (D)	0	0	0	0	0	0	0	0	0	0	2	0
	20	10	11	10	11	10	18	8	10	11	11	11
" " (T)	2	2	1	0	1	0	0	0	0	0	0	0
	37	23	19	16	21	16	25	16	11	16	7	10
Hepatocytic Necrosis and Inflammation (D)	0	0	0	0	0	0	0	2	0	0	2	0
	20	10	11	10	11	10	18	8	10	11	11	11
Hepatocytic Necrosis and Inflammation (T)	3	1	3	0	0	0	0	1	0	0	1	0
	37	23	19	16	11	16	25	16	11	16	7	10
*Congested/Dilated Contri- lobular Sinusoids (D)	0	0	0	0	0	3	0	1	0	1	1	1
	20	10	11	10	11	10	18	8	10	11	11	11
*Congested/Dilated Contri- lobular Sinusoids (T)	0	0	0	2	8	6	1	0	0	0	0	2
	37	23	19	16	21	16	25	16	11	16	7	10
*Brown Pigmented Kupffer Cells (T)	0	0	0	0	0	1	0	1	0	0	3	1
	20	10	11	10	11	10	18	8	10	11	11	11
*Brown Pigmented Kupffer Cells (T)	0	0	0	0	1	4	0	0	0	0	1	2
	37	23	19	16	21	16	25	16	11	16	7	10
*Fat Deposition (D)	7	10	10	5	4	8	5	2	8	7	9	9
	20	10	11	10	11	10	18	8	10	11	11	11
" " (T)	20	5	3	6	6	5	4	5	1	6	4	8
	37	23	19	16	21	16	25	16	11	16	7	10
Pancreas												
Fat Necrosis (D)	0	0	0	0	0	0	0	0	0	0	0	0
	20	10	11	10	11	10	0	0	0	0	0	0
" (T)	1	0	0	0	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Kidneys												
Glomerulonephritis (D)	0	0	0	0	0	0	0	0	0	0	1	0
	20	10	11	10	11	10	18	8	10	11	11	11
" (T)	3	0	1	1	0	1	1	1	0	0	0	0
	37	23	19	16	21	16	25	16	11	16	7	10
Perivascular Lymphoid Aggregations (D)	0	1	0	0	0	0	0	1	2	1	1	1
	20	10	11	10	11	10	18	8	10	11	11	11
Perivascular Lymphoid Aggregations (T)	2	1	1	2	2	5	4	3	1	2	1	3
	37	23	19	16	21	16	25	16	11	16	7	10
Cystic Tubules (D)	0	0	0	0	0	0	0	0	0	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11

14

11. Histopathological Findings to the Nonneoplastic Lesions - Continued

004075

Dose Levels (ppm)	Males						Females					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
<u>Kidneys</u>	0	2	0	0	0	0	0	0	1	0	0	0
Cystic Tubules (T)	37	23	19	16	16	16	25	16	11	16	7	10
	0	0	0	0	1	0	0	0	0	0	0	0
Urinary Bladder (D)	20	10	11	10	10	10	18	8	10	11	11	11
" (T)	1	0	1	0	2	0	0	0	0	0	0	0
	37	23	9	16	21	16	25	16	11	16	7	9
<u>Uterus</u>												
Dilated Lumen (D)	0	0	0	0	0	0	2	0	3	1	3	2
" (T)	0	0	0	0	0	0	18	8	10	11	11	11
	0	0	0	0	0	0	1	1	0	0	2	3
Cystic Endometrial Hyperplasia (D)	0	0	0	0	0	0	25	16	11	16	7	10
Cystic Endometrial Hyperplasia (T)	0	0	0	0	0	0	0	0	0	1	1	0
Distended Lumen (D)	0	0	0	0	0	0	18	8	10	11	11	11
" (T)	0	0	0	0	0	0	9	4	2	0	1	1
	0	0	0	0	0	0	25	16	11	16	7	10
	0	0	0	0	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	18	8	10	11	11	11
	0	0	0	0	0	0	6	4	2	5	3	4
	0	0	0	0	0	0	25	16	11	16	7	10
<u>Ovaries</u>												
Angiectasis (D)	0	0	0	0	0	0	0	0	0	1	0	0
" (T)	0	0	0	0	0	0	18	8	10	11	11	11
	0	0	0	0	0	0	0	1	1	2	1	1
	0	0	0	0	0	0	25	16	11	16	7	10
<u>Prostate</u>												
Prostatitis (D)	0	0	0	0	0	0	0	0	0	0	0	0
" (T)	20	10	11	10	10	10	0	0	0	0	0	0
	0	0	0	1	0	0	0	0	0	0	0	0
	37	23	19	15	21	16	0	0	0	0	0	0
<u>Seminal Vesicles</u>												
Distended with Colloid (D)	0	1	3	2	1	0	0	0	0	0	0	0
Distended with Colloid (T)	20	10	11	10	11	10	0	0	0	0	0	0
	9	11	7	4	8	4	0	0	0	0	0	0
	37	23	19	15	21	16	0	0	0	0	0	0
<u>Testes</u>												
Spermatocetes (D)	1	0	0	0	1	0	0	0	0	0	0	0
" (T)	20	10	11	10	11	10	0	0	0	0	0	0
	6	5	3	1	2	5	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Reduced Spermatogenesis (D)	0	0	0	0	0	1	0	0	0	0	0	0
Reduced Spermatogenesis (T)	20	10	11	10	11	10	0	0	0	0	0	0
	7	7	2	1	5	4	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Atrophic Seminiferous Tubules (D)	2	0	0	0	0	0	0	0	0	0	0	0
Atrophic Seminiferous Tubules (T)	20	10	11	10	11	10	0	0	0	0	0	0
	7	4	2	1	4	3	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
<u>Thyroids</u>												
Cystic Follicles (D)	0	0	0	0	0	0	0	0	0	0	0	0
" (T)	19	10	11	10	11	10	18	8	10	11	11	11
	0	0	1	0	1	0	0	1	2	0	0	0
	37	22	19	16	21	16	25	16	11	16	7	10

17

11. Histopathological Findings to the Nonneoplastic Lesions - Continued

004075

Dose Levels (ppm)	Males						Females					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
<u>Adrenals</u>												
Medullary Hyperplasia (D)	0	0	0	0	0	0	0	0	0	0	0	0
	20	10	10	10	10	10	18	8	10	11	11	10
" (T)	0	1	0	1	0	2	0	0	0	0	0	0
	37	23	19	16	21	16	24	16	11	16	11	10
Prominent Ceroid Cells (D)	1	0	1	0	1	0	1	0	0	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11
Prominent Ceroid Cells (T)	5	4	2	3	4	3	11	4	1	2	2	4
	37	23	19	16	21	16	24	16	11	16	7	10
<u>Pituitary</u>												
Pituitary Cysts (D)	0	0	1	0	0	0	0	0	0	0	0	0
	20	10	11	10	11	10	0	0	0	0	0	0
" (T)	0	1	1	1	0	1	0	0	0	0	0	0
	37	22	19	15	19	15	0	0	0	0	0	0
<u>Stomach</u>												
Epithelial Hyperplasia (ng) (D)	4	1	2	1	0	1	3	2	2	4	2	0
	20	10	11	10	11	10	18	8	10	11	11	11
Epithelial Hyperplasia (ng) (T)	0	0	0	0	0	0	0	0	0	0	0	0
	37	23	19	16	21	16	25	16	11	16	7	10
Acanthosis (D)	0	1	0	0	0	0	0	0	0	1	0	1
	20	10	11	10	11	10	18	8	10	11	11	11
Acanthosis (T)	1	1	1	1	0	6	4	0	0	3	0	3
	37	23	19	16	21	16	25	16	11	16	7	10
Adenomatous Hyperplasia (g) (D)	1	1	0	1	0	1	1	0	0	0	0	0
	20	10	11	10	11	10	18	8	10	11	11	11
Adenomatous Hyperplasia (g) (T)	3	2	1	2	2	0	1	1	1	0	2	0
	37	23	19	16	21	16	25	16	11	16	7	10
<u>Eyes</u>												
Lenticular Fibre Degeneration (D)	0	0	0	0	0	0	0	0	0	0	0	0
	20	10	11	10	11	10	0	0	0	0	0	0
Lenticular Fibre Degeneration (T)	1	2	2	0	1	1	0	0	0	0	0	0
	37	23	19	16	21	16	0	0	0	0	0	0
Keratitis (D)	0	0	0	0	0	0	1	0	1	0	1	0
	0	0	0	0	0	0	18	8	10	11	11	11
" (T)	0	0	0	0	0	0	1	0	0	1	0	2
	0	0	0	0	0	0	25	16	11	16	7	10
<u>Skin</u>												
Ulcers (D)	0	0	0	0	0	1	0	0	0	0	0	0
	1	1	0	0	1	1	0	0	0	0	0	0
" (T)	0	1	0	0	1	0	0	0	0	0	0	0
	0	1	1	0	2	0	0	0	0	0	0	0

* Noticeable increase of incidence rate (%); (D) - Interim kill after 52 weeks of treatment; (T) - Terminal kill.

A

11. Histopathological Findings to the Nonneoplastic Lesions - Continued

004075

Summary of Nonneoplastic Findings:

The following treatment-related nonneoplastic changes from the treated mice at the spordic deaths and terminal sacrifices were summarized:

Dose Levels (ppm)	Males						Females					
	0	16	80	400	2000	10000	0	16	80	400	2000	10000
<u>Lung</u>												
Chronic Pneumonitis	11 104 11%	6 51 12%	10 52 19%	10* 52 19%	13* 52 25%	13* 52 25%	18 104 17%	7 52 13%	8 52 15%	4 52 8%	2 52 4%	7 51 14%
<u>Spleen</u>												
Extramedullary Haemopoiesis	27 104 26%	7 52 14%	15 21 29%	21 52 40%	19* 52 37%	22* 52 42%	37 104 36%	18 52 35%	19 52 37%	19 52 37%	25* 52 48%	25* 52 48%
Siderocytes	5 104 5%	1 52 2%	2 52 4%	16 52 31%	32* 52 62%	30* 52 58%	15 104 14%	6 52 12%	13* 52 25%	30* 52 58%	31* 52 59%	43* 52 83%
<u>Liver</u>												
Hepatocyte Enlargement	36 104 35%	12 52 23%	11 52 21%	23 52 44%	35* 52 67%	31* 52 57%	15 104 14%	4 52 8%	5 52 10%	11 52 21%	15* 52 29%	29* 52 56%
Extramedullary Haemopoiesis	4 104 4%	3 52 6%	0 52 0%	3 52 6%	12 52 23%	15* 52 29%	8 104 8%	4 52 8%	2 52 4%	5 52 10%	2 52 4%	5 52 10%
Hepatocyte Vacuolation	22 104 21%	17 52 33%	9 52 17%	12 52 35%	18 52 50%	26* 52 32%	33 104 33%	17 52 33%	17 52 33%	17 52 33%	12 52 23%	26* 52 50%
Congested/Dilated Contrilobular Sinusoids	0 104 0%	0 52 0%	0 52 0%	2 52 4%	8* 52 16%	6* 52 12%	1 104 1%	0 52 0%	0 52 0%	0 52 0%	0 52 0%	2* 52 4%
Brown Pigmented Kupffer Cells	0 104 0%	0 52 0%	1 52 2%	1 52 2%	3 52 6%	11* 52 21%	1 104 1%	0 52 0%	1 52 2%	0 52 0%	4* 52 8%	11* 52 21%
Fat Deposition	36 104 35%	18 52 35%	10 52 19%	10 52 19%	13 52 25%	16 52 31%	24 104 23%	9 52 17%	7 52 13%	16 52 31%	12 52 23%	21 52 40%

* Significantly treatment-related increase of incidence.

19

Evaluation and Conclusions:

1. There were no obvious treatment-related effects on mortality, body weights, and food consumption in male and female mice fed Diflubenzuron in the diet during the course of the study.
2. The blue/gray discoloration of the extremities and dark eyes were persistently observed in male and female mice treated with Diflubenzuron throughout the entire study period. Such abnormal clinical signs of cyanosis were apparently caused by the significantly dose-related elevation of methemoglobin and sulfhemoglobin levels in the treated mice of both sexes during the course of the study (1-91 weeks). These results were also correlated well with the abnormal hematology values noted in the increased mean corpuscular hemoglobin concentration, mean corpuscular hemoglobin value and Heinz bodies from the same treated groups. The presence of increased amounts of methemoglobin and sulfhemoglobin in blood can result in an impairment of oxygen transport with consequent peripheral hypoxia and other cardiac effects. The symptoms in such cases are due secondarily to damage the central nervous system and/or the heart, and the organs most sensitive to oxygen lack. Therefore, the no-effect-level of Diflubenzuron for methemoglobinemia and sulfhemoglobinemia in male and female mice must be clearly established in this study.
3. Treatment-related histomorphologic lesions were observed in the spleen, skin, livers and lungs of treated mice of both sexes. The increased incidences of splenic enlargement, and enlarged livers were detected among Diflubenzuron-treated mice of both sexes at 2000 and 10000 ppm. These results were correlated well with the significant increases of incidence in the higher spleen and liver weights of the same treated groups. The high incidences of congested lungs were also detected in the treated males receiving 2000 and 10000 ppm Diflubenzuron with no effect of treatment on female at the terminal kill. There appears to be some correlation in the increase of incidence rate between the congested lungs and the inflammation of the lungs (chronic pneumonitis) from the treated male groups.
4. The significantly treatment-related nonneoplastic lesions (chronic pneumonitis in the lung, extramedullary haemopoiesis and siderocytes in the spleen, hepatocyte enlargement, hepatocyte vacuolation, extramedullary haemopoiesis, congested/dilated contrilobular sinusoids, brown pigmented kupffer cells, and fat deposition in the liver) in the treated mice of both sexes were shown in the summarized results No. 11. These results produce evidence of definite histological effects in the spleens, livers, and lungs of orally dosed mice. However, the increased incidences of angiectasis in the ovaries, medullary hyperplasia and prominent ceroid cells in the adrenals, and acanthosis in the stomach found in the treated animals cannot be evaluated properly without the historical control data of the CFLP mice. No other nonneoplastic lesions in a variety of organ tissues from treated mice of both sexes were considered to be significantly different from the control groups.

004075

5. Neoplastic lesions were sporadically distributed among the treated and untreated mice and are summarized in the results No. 10. No neoplastic lesions in a variety of organ tissues from treated mice of both sexes were considered to be significantly different from the control groups. These results produce no evidence of carcinogenicity of Diflubenzuron in the treated CFLP mice at the dose levels tested (16 through 10000 ppm).
6. Classification of Data:

This study is adequate to be rated core guideline for oncogenic potential. However, the studies in chronic feeding and nonneoplastic effects are judged inadequate to be acceptable. Until the reporting deficiencies cited in our conclusion #2 and #4 (e.g., No effect level for methemoglobin and sulfhemoglobin in treated mice was not determined, and all historical control data were missing for the increased incidencies of angiectasis in the ovaries, medullary hyperplasia and prominent ceroid cells in the adrenals, and acanthosis in the stomach of treated mice) are clarified and resolved, these studies remain to be rated supplementary and cannot be upgraded to core (minimum or guideline).